-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
What does the future hold for uveal melanoma, a historically untreatable disease?
Alexander N Shoushtari , Richard D Carvajal
Editorial: Clinical Investigation
-
What does the future hold for uveal melanoma, a historically untreatable disease?
Alexander N Shoushtari , Richard D Carvajal
Editorial: Clinical Investigation
-
What does the future hold for uveal melanoma, a historically untreatable disease?
Alexander N Shoushtari , Richard D Carvajal
Editorial: Clinical Investigation
-
What does the future hold for uveal melanoma, a historically untreatable disease?
Alexander N Shoushtari , Richard D Carvajal
Editorial: Clinical Investigation
-
What does the future hold for uveal melanoma, a historically untreatable disease?
Alexander N Shoushtari , Richard D Carvajal
Editorial: Clinical Investigation
-
What does the future hold for uveal melanoma, a historically untreatable disease?
Alexander N Shoushtari , Richard D Carvajal
Editorial: Clinical Investigation
-
HIV pre-exposure prophylaxis trials: the road to success
Melanie R Nicol, Jessica L Adams, Angela DM Kashuba
Review: Clinical Trail Outcomes: Clinical Investigation
-
HIV pre-exposure prophylaxis trials: the road to success
Melanie R Nicol, Jessica L Adams, Angela DM Kashuba
Review: Clinical Trail Outcomes: Clinical Investigation
-
HIV pre-exposure prophylaxis trials: the road to success
Melanie R Nicol, Jessica L Adams, Angela DM Kashuba
Review: Clinical Trail Outcomes: Clinical Investigation
-
HIV pre-exposure prophylaxis trials: the road to success
Melanie R Nicol, Jessica L Adams, Angela DM Kashuba
Review: Clinical Trail Outcomes: Clinical Investigation
-
HIV pre-exposure prophylaxis trials: the road to success
Melanie R Nicol, Jessica L Adams, Angela DM Kashuba
Review: Clinical Trail Outcomes: Clinical Investigation
-
HIV pre-exposure prophylaxis trials: the road to success
Melanie R Nicol, Jessica L Adams, Angela DM Kashuba
Review: Clinical Trail Outcomes: Clinical Investigation
-
Genetic biomarkers of placebo response: what could it mean for future trial design?
Kathryn T Hall & Ted J Kaptchuk
Editorial: Clinical Investigation
-
Genetic biomarkers of placebo response: what could it mean for future trial design?
Kathryn T Hall & Ted J Kaptchuk
Editorial: Clinical Investigation
-
Genetic biomarkers of placebo response: what could it mean for future trial design?
Kathryn T Hall & Ted J Kaptchuk
Editorial: Clinical Investigation
-
Genetic biomarkers of placebo response: what could it mean for future trial design?
Kathryn T Hall & Ted J Kaptchuk
Editorial: Clinical Investigation
-
Genetic biomarkers of placebo response: what could it mean for future trial design?
Kathryn T Hall & Ted J Kaptchuk
Editorial: Clinical Investigation
-
Genetic biomarkers of placebo response: what could it mean for future trial design?
Kathryn T Hall & Ted J Kaptchuk
Editorial: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus
Ricard Cervera, Gerard Espinosa
Review Article: Clinical Investigation
-
Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus
Ricard Cervera, Gerard Espinosa
Review Article: Clinical Investigation
-
Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus
Ricard Cervera, Gerard Espinosa
Review Article: Clinical Investigation
-
Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus
Ricard Cervera, Gerard Espinosa
Review Article: Clinical Investigation
-
Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus
Ricard Cervera, Gerard Espinosa
Review Article: Clinical Investigation
-
Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus
Ricard Cervera, Gerard Espinosa
Review Article: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation